Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that a clinical study featuring 68Ga-Trivehexin (68Ga-RAD 301), conducted by Dr. Rehm and colleagues from the Technische Universität Dresden, has now been…
Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress…
Description During a fireside chat with analysts from Brookline Capital Markets, Radiopharm Theranostics’ (ASX:RAD) CEO Riccardo Canevari provided clinical…
Gunnison Copper (TSX:GCU,OTCQB:EXMGF) is shifting its development strategy for the Gunnison copper project in Arizona, US, laying out plans…
Provaris Energy Ltd (ASX.PV1, Provaris, the Company) is pleased to present the notice of initial substantial holder. Click here…
Lightning Minerals (L1M or the Company) is delighted to announce the discovery of spodumene within a lithium bearing pegmatite…
Syntheia Corp. (‘Syntheia’ or the ‘Company’) (Syntheia.ai), CSE SYAI, a Canadian leader in conversational AI, announces that its innovative…
The Board of CleanTech Lithium announces that the Company has received the following TR-1 notification which is set out…
Alvopetro Energy Ltd. (TSXV: ALV) (OTCQX: ALVOF) (‘Alvopetro’ or the ‘Company’) announces the annual rolling grants of long-term incentive…